The ASGCT data provides mechanistic validation for agenT-797's dual-mode activity, de-risking the platform and supporting the upcoming Phase 2 trial in acute lung injury. Monitor for preliminary Phase 2 data in 2026, which could be a major catalyst. The broad applicability across oncology and critical care expands the addressable market.
INKT drugs
INKT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $11.41entry
- T+1 · 6mo ago −3.16%α −3.73% · $11.05
- T+5 · 6mo ago −12.01%α −12.08% · $10.04
- T+20 · 5mo ago +6.84%α +8.56% · $12.19
- T+60 · 3mo ago −3.59%α −7.98% · $11.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context-dependent immune responses (pro-inflammatory in cancer, anti-inflammatory in ARDS) from the same manufacturing batch without genetic engineering. The data supports advancement into a randomized Phase 2 trial in acute lung injury, with preliminary results expected in 2026.
Key Facts
- agenT-797 drove TH1 pro-inflammatory immune program in 34 solid tumor patients and TH2 anti-inflammatory response in 20 ARDS patients from the same donor batch.
- Data includes complete metastatic remission in germ cell testicular cancer (agenT-797 + anti-PD-1) and improved survival/pathogen clearance in severe ARDS.
- Favorable safety profile: no uncontrolled cytokine release syndrome or pathologic hyperinflammation.
- Company advancing to randomized Phase 2 trial in acute lung injury (C-1300-02) with preliminary data expected in 2026.
- Manufacturing platform scalable: reproducible across multiple batches and donors, producing billions of cells per donor.
Financial Impact
No financial figures disclosed; potential value depends on Phase 2 trial outcomes and eventual commercialization.
Risk Factors
- Phase 2 trial results may not replicate Phase 1/2 findings.
- Competition from other cell therapy platforms and existing ARDS treatments.
- Regulatory and manufacturing scale-up risks for allogeneic cell therapy.
- Company has limited cash runway (market cap $55M) and may need to raise capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292728 |
Track record
21 reports on INKT
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers